Table 2. Mean (±SEM) Locomotor Activity, Response Latencies, and Omissions During Probabilistic Discounting or Reward Magnitude Discrimination.

Probabilistic discounting	Locomotor activity (beam breaks/min)	Response latency (s)	Omissions (no. of trials per session)
Antagonists
SCH 23 390
1 μg	32.9 (5.2)*	1.2 (0.1)*	3.2 (1.6)*
0.1 μg	37.4 (4.9)	1.0 (0.2)	2.1 (1.2)
Saline	42.5 (5.0)	0.9 (0.1)	0.5 (0.3)
Eticlopride
1 μg	24.6 (2.2)*	0.7 (0.1)	1.1 (0.9)
0.1 μg	30.8 (2.6)	0.8 (0.1)	0.1 (0.1)
Saline	29.4 (2.9)	0.6 (0.1)	1.0 (0.5)
Agonists
SKF 81 297
2 μg	36.8 (3.2)	0.6 (0.1)	0.7 (0.3)
0.2 μg	36.1 (3.3)	0.7 (0.1)	0.3 (0.2)
Saline	34.5 (3.9)	0.6 (0.1)	0.5 (0.3)
Quinpirole
10 μg	43.1 (5.7)	0.6 (0.0)	0.7 (0.4)
1 μg	36.1 (3.7)	0.6 (0.1)	0.2 (0.1)
Saline	37.7 (5.2)	0.6 (0.1)	0.8 (0.4)
Bromocriptine
10 μg	36.9 (3.9)	0.9 (0.6)	1.5 (0.8)
1 μg	38.0 (3.1)	0.9 (0.3)	2.8 (1.4)
Vehicle	35.3 (4.1)	0.9 (0.2)	1.5 (0.9)
PD 128 907
3 μg	35.2 (4.5)	0.8 (0.1)	0.8 (0.4)
1.5 μg	28.9 (2.9)	0.9 (0.1)	0.6 (0.3)
Saline	35.6 (4.9)	0.8 (0.1)	0.3 (0.1)
Reward magnitude
SCH 23 390 (1 μg)	27.0 (3.9)	0.9 (0.1)	2.3 (2.3)
Saline	33.6 (4.1)	0.8 (0.1)	0.1 (0.1)
PD 128 907 (1.5 μg)	47.5 (4.7)	0.9 (0.1)	0.2 (0.2)
Saline	44.9 (2.8)	0.8 (0.1)	0.2 (0.2)

*p<0.05 vs saline.